The Accelerate, Redesign, and Collaborate (ARC) innovation centre at Israel’s Sheba Medical Center has partnered with Revealense to develop an AI-based diagnostic for evaluating neurological conditions.
Underpinned by Revealense’s AI behavioural analysis platform, the diagnostic will take the form of a webcam for at-home evaluation. The tool will assess an individual's condition by factoring in potential environmental influences, monitoring changes over time, and recommending personalised care plans for each user.
Sheba Medical Center’s child development centre director, Dr Omer Bar Yosef, will serve as project lead.
According to the parties, the finalised product will achieve clinically validated diagnoses across a wide range of neurological, cognitive, and developmental conditions. However, the project will initially establish diagnostic protocols for autism spectrum disorder (ASD), ADHD, which research indicates has a high comorbidity rate with ASD, and related conditions.
Revealense CEO Dov Donin claims the collaboration could lead to a “profound shift” in how neurological disorders are understood, diagnosed, and treated.
According to Donin, a combination of computational models, psychophysiological measurements, and real-time monitoring holds the potential to “elevate the entire diagnostics landscape”.
The current ASD diagnostic landscape
The DSM-5 criteria, a standardised system for classifying a range of brain-related conditions, have long been viewed as the gold standard for diagnosing ASD. However, research indicates that challenges in assessment access result in high rates of underdiagnosis. A 2023 population-level study estimated that 750,000 UK adults may be undiagnosed with ASD while research from the US suggests that up to two million adults may be undiagnosed.
Sheba Impact CEO Avner Halperin commented: “This partnership will enable a faster neurological diagnostic process with increased accuracy and reliability, while improving accessibility by moving from the clinic to home.”
ARC and Revealense’s partnership continues the growing trend for AI-based ASD diagnostics, yet the field currently remains small.
In 2024, Cognoa’s AI-based child autism diagnostic became available as a covered benefit under Wyoming Medicaid. The device, which uses data collection and AI to aid in the clinical evaluation of ASD, gained de novo clearance from the FDA in 2021 for ASD diagnosis in children aged 18 months to six years.
In January 2025, Schweitzer Engineering Laboratories (SEL) announced plans to expand into the medical device sector to produce a diagnostic for early ASD.
The National Institutes of Health (NIH) and the US Centers for Medicare & Medicaid Services (CMS) announced plans in May to develop a real-world data platform in the US that some observers said would amount to a registry for individuals with ASD.
US Health Secretary Robert F Kennedy, Jr (RFK Jr) claimed the initiative would help determine the ‘root cause’ of ASD ‘by September 2025. RFK Jr, who has previously shared the widely debunked claim that vaccines cause autism, faced consternation by the wider autism community. A petition was filed against the plans, branding the mooted platform a "slippery slope to eugenics".
